Capillary Film Technology Receives £1 Million Funding to Develop a Point-of-Care Acute Coronary Syndrome Diagnostic
Capillary Film Technology (CFT), a UK-based technology and product development company for life sciences and clinical diagnostics, has received £1 million in funding through a Phase 2 Small Business Research Initiative for Healthcare (SBRI Healthcare) development contract. CFT will use the funding to work with partners to develop a prototype of its cost-effective and fully quantitative multiplexed point-of-care (POC) microfluidic testing technology to diagnose acute coronary syndrome. The prototype will then be clinically validated in hospitals around the UK in preparation for regulatory approval.
The phase 2 funding follows on from a successful £98,000 Phase 1 SBRI Healthcare feasibility contract, which was awarded to CFT in April earlier this year to demonstrate the feasibility of CFT’s micro capillary film in a POC setting in measuring heart attack biomarkers. The technology is based upon a low-cost microfluidic fluoropolymer film with unique optical transparency that delivers extremely sensitive measurements within 10 or more microcapillaries. This allows fully quantitative immunoassays against multiple biomarkers to be performed from a single sample. Panels of existing or emerging diagnostic biomarkers can therefore be measured using MCF technology at the point of care with performance matching that of laboratory assays. MCF technology provides a cost effective and both highly sensitive and fully quantitative option for diagnosing acute coronary syndrome (heart attack), resulting in reduced waiting times and improved treatment for patients.
Commenting on the funding, Dr Lee Smith, CEO at CFT, said: “In the UK and US, coronary heart disease is the leading cause of death. CFT was selected by SBRI to develop a test for use in NHS accident and emergency departments to diagnose myocardial infarction. Our next-generation lateral flow diagnostic testing technology has the potential to save the NHS up to £65 million per year by rapidly identifying those individuals who have a serious heart complaint whilst allowing those who have not suffered a heart attack to be rapidly and confidently discharged instead of being admitted. This Phase 2 contract will be transformational for CFT. It validates the platform and will support us as we identify partners to co-develop this technology, which will improve the care of patients suffering from heart attacks.”
Commenting on the company’s proposed approach, Technology Co-founder and Director at CFT, Dr Nuno Reis, added: “CFT’s disruptive microfluidic technology is capable of repackaging highly precise and sensitive laboratory immunoassay equipment into an affordable and portable format with multiplex detection capability. Furthermore there is no need for complicated sample preparation since the assays can simply be performed in whole blood.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance